Document:

Exhibit 4.36

AMENDMENT AGREEMENT

As of March 30, 2011

This Amendment Agreement (this “Agreement”) is entered into by and among IASO Pharma Inc. (f/k/a Pacific Beach Biosciences, Inc.), a Delaware corporation (the “Company”), and
Capretti Grandi, LLC (“Holder”). 

RECITALS

WHEREAS, Holder is the holder of an Amended and Restated Future Advance Promissory dated as of September 30,
2009 made by the Company in favor of Holder (as previously amended, the “Note”);

WHEREAS, the Company filed a registration statement with the SEC and conducted a road show for a proposed
initial public offering (“IPO”) of the Company’s securities led by Ladenburg Thalmann & Co. Inc. (“Ladenburg”) in February 2011; however, despite the considerable efforts of all involved, the IPO failed to price and was not consummated;

WHEREAS, the Company has determined that it is in the best interest of the Company and its stockholders to
obtain interim financing and retain its lead asset is to conduct a rights offering (the “Rights Offering”) to its existing convertible noteholders, including the Holders,
of a new issue of secured convertible notes in the aggregate principal amount of $3,000,000 (the “Rights Offering Notes”), with each existing convertible noteholder, including the Holders entitled to purchase up to $281 in principal amount of Rights Offering Notes for each $1,000 of
original principal amount of existing convertible notes held by such noteholder. The Rights Offering Notes will be secured by all the assets of the Company and
will be convertible into 100% of the equity of the Company immediately prior to an IPO; provided, however, that the Company will have the right to repay up to
$1 million of the Rights Offering Notes out of the proceeds of an IPO. The terms of the Rights Offering will be more fully described in the Subscription Form
and Subscription Agreement that will be circulated to you once the Requisite Approval (as defined below) is obtained in connection with this Agreement;

WHEREAS, the Rights Offering will be backstopped by Dr. Lindsay A. Rosenwald and Manchester Securities Corp.
(“Manchester”) (or their respective affiliates), the Company’s two largest investors. As compensation for their backstop commitment, Dr.
Rosenwald and Manchester will receive warrant coverage to purchase shares equal to 100% of their backstop commitment amounts; however, Dr. Rosenwald will assign
his backstop warrants to all the existing convertible noteholders of the Company (other than Manchester) on a pro rata basis.  The backstop warrants to be
issued to Manchester will contain certain anti-dilution protections that will not be in the warrants to be issued to Dr. Rosenwald.  In addition, following
consummation of the Rights Offering, Manchester and Dr. Rosenwald will have the right to consent to any material action taken by the Company prior to the
consummation of an IPO and Manchester will have the right to designate one member of the Company’s board of directors;

WHEREAS, the Rights Offering is
designed as a bridge to a larger financing, ideally an IPO.  With respect to the larger financing, the Company has engaged in discussions with OPN Capital
Markets, a division of National Securities (“OPN”), to act as co-lead underwriter in connection with an IPO.  OPN is a joint venture of Opus
Point Partners and National Securities.  Dr. Rosenwald is a principal of Opus Point Partners, which is a significant shareholder of National Securities.
 Based on discussions with OPN and feedback from Ladenburg, the Company believes it is imperative that the Company effect a recapitalization that permits a
lower pre-money valuation to give it the best chance for successfully

completing an IPO.  As such, the
Company is seeking to effect a substantial recapitalization that would amend, in accordance with the terms set forth herein, the Note and all the Company’s
other existing convertible notes;  

WHEREAS, in connection with the proposed recapitalization and the Rights Offering, all of the Company’s
investor warrants will be terminated and the Company will effect a reverse stock split so that all of the current equity in the Company is effectively
eliminated, and the shares into which the Rights Offering Notes convert will represent substantially all of the capital stock in the Company immediately prior
to the consummation of an IPO. Following the proposed recapitalization and the Rights Offering, the only debt the Company will have outstanding will be
amounts borrowed under its bank line of credit, which amounted to $325,000 as of December 31, 2010 and which is expected to be repaid with the proceeds of an
IPO, and the notes issued to Paramount Credit Partners in the aggregate amount of $2,875,000, which are not convertible and will not be repaid with the proceeds
of an IPO;

WHEREAS, the Company seeks the consent of the Holder to amend the Note to provide that the Note will convert
into the right to receive Milestone Payments (as defined herein) upon the consummation of the Rights Offering, on the terms set forth herein, in order to effect
the proposed recapitalization and maximize the Company’s ability to complete an IPO; and

WHEREAS, the Holder agrees to amend
the Note on the terms set forth herein; 

AMENDMENTS

NOW, THEREFORE, the parties agree as follows:

1.

Amendments to the Note.   

(a)

The Note is hereby amended to
extend the Due Date of the Note from March 31, 2011 to June 30, 2011.

(b)

Section 2 of the Note is hereby
amended to add the following as a new subsection 2.3:

2.3

(a)

Notwithstanding any provision to the
contrary herein, including the provisions contained in Sections 2.1 and 2.2 above, upon the Consummation of a Rights Offering, all unpaid principal and accrued
but unpaid interest on the Note shall be automatically converted into the right to receive the Holder’s Pro Rata Share (as defined below) of the Milestone
Payments (as defined below) set forth in (b) and (c) below.

(b)

Upon the achievement by the Company (or
its Affiliates or Sublicensees) of the milestone events described below (each, a “Development Milestone Event”), the Company shall pay to the
Holder its Pro Rata Share of the milestone payment specified below (each, a “Development Milestone Payment”).  The specified Development
Milestone Payment shall be made within thirty (30) days after the occurrence of the related Development Milestone Event.  

		
	Development Milestone Event 

	Milestone Payment

	 	 
	Successful Completion of first Phase III
Clinical Trial

	$2,500,000

2

		
	FDA acceptance for review of first NDA

	$2,500,000

	 	 
	FDA Final Approval of first NDA

	$5,000,000

	 	 

(c)

Following the First Commercial Sale of
the Product, the Company shall (i) pay to the Holder, upon the terms and subject to the conditions hereof, the Holder’s Pro Rata Share of the Net Sales
Payment (as defined below) for each calendar quarter until such time as the cumulative Net Sales (as defined below) by the Company and its Affiliates and
Sublicensees reach an aggregate of $150,000,000 and (ii) provide Holder with a statement along with such payment, such statement to be certified by the Chief
Financial Officer of the Company, setting forth the Company’s calculation of both the Net Sales and the Net Sales Payment for such calendar quarter.
 The Net Sales Payment for each calendar quarter shall be made within sixty (60) days after the end of such calendar quarter, but in any event no later
than the date on which the Company makes its quarterly royalty payment based on Net Sales to the Licensor under the License Agreement.

(d)

If the Company is a public reporting
company under the Securities Exchange Act of 1934, as amended, at the time any Milestone Payment is due, the Company may, at its option, issue shares of Common
Stock having a value equal to the amount of such Milestone Payment in lieu of making such Milestone Payment in cash, with such value determined based on the
average closing price of the Common Stock during the twenty (20) Trading Days immediately preceding the date on which such Milestone Payment is due; provided
that (i) such shares of Common Stock are registered under the Securities Act and are issued under an effective registration statement of the Company under the
Securities Act and (ii) all Equity Conditions are satisfied.  As soon as practicable, but in no event more than two Trading Days, following the public
announcement by the Company of any Development Milestone Event or earnings for a calendar quarter with respect to which a Net Sales Payment is due (the “Milestone Payment Notice Date”), the
Company shall send to the Holder a written notice (a “Milestone Payment Notice”) that shall
state whether the entire applicable Milestone Payment shall be paid in cash or in shares of Common Stock and if such payment is to be made in shares of Common
Stock, certify that the Equity Conditions are then satisfied.  If (x) the Company does not timely send a Milestone Payment Notice to Holder in accordance
with this Section 2.3(d) or (y) the Equity Conditions are not satisfied, then the Company shall be deemed to have delivered a Milestone Payment
Notice electing to pay the entire Milestone Payment in cash. Each Milestone Payment Notice, whether actually given or deemed given, shall be irrevocable.
 Any shares of Common Stock issued pursuant to this Section 2.3(d) shall be delivered to the Holder no later than three (3) Trading Days following
the date on which the applicable Milestone Payment is due.

(e)

Upon the Consummation of a Rights
Offering, the outstanding unpaid principal and accrued but unpaid interest of the Note shall be converted without any further action by the Holder and whether
or not the Note is surrendered to the Company or its transfer agent, and the indebtedness evidenced by this Note shall be satisfied in full and no interest
shall continue to accrue on this Note and all rights of the Holder hereunder shall terminate. The Company shall not be obligated to issue any certificate or
other instrument evidencing the Holder’s right to receive the Holder’s Pro Rata Share of the Milestone Payments. Any conversion effected in accordance
with this Section 2 shall be binding upon the Holder hereof.

3

(f)

For purposes of this Section 2.3, the
following terms shall have the following meanings: 

“Affiliate” shall
mean, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under common control with, such Person.
 A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least fifty percent (50%) of the voting
stock or other ownership interest of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management
and policies of the other Person by any means whatsoever;

“Consummation of a Rights
Offering” means the consummation of a Rights Offering on or before June 30, 2011;

“Equity Conditions”
shall mean each of the following:  (i) on each day during the Equity Conditions Measuring Period, the shares of Common Stock are designated for listing on
a national securities exchange and shall not have been suspended from trading on such exchange nor shall delisting or suspension by such exchange have been
threatened or pending in writing by such exchange nor shall there be any SEC or judicial stop trade order or trading suspension stop order; (ii) any shares of
Common Stock to be issued in connection with the applicable Milestone Payment may be issued in full without violating the rules or regulations of the national
securities exchange on which they are listed or any applicable laws; (iii) on each day during the Equity Conditions Measuring Period, there shall not have
occurred and be continuing, unless waived by the Holder, either (A) an Event of Default or (B) an event that with the passage of time or giving of notice would
constitute an Event of Default; (iv) on each day during the Equity Conditions Measuring Period, the Company has not provided any Holder with any material
non-public information concerning the Company, except pursuant to a confidentiality agreement between the Company and such Holder; (v) the Company’s
transfer agent for the shares of Common Stock is participating in the DTC Fast Automated Securities Transfer Program; and (vi) all shares of Common Stock to be
issued in connection with the applicable Milestone Payment are duly authorized and will be validly issued, fully paid and non-assessable upon issuance and the
issuance thereof will not require any further approvals of the Company’s board of directors or shareholders.

“Equity Conditions Measuring
Period” shall mean the period beginning twenty (20) Trading Days prior to the date of the applicable Milestone Payment and ending on and including such
date.

“Existing Convertible Notes” shall mean the means:
(i) the Note; (ii) the Amended and Restated Future Advance Promissory Notes dated as of September 30, 2009 made by the Company
in favor of each of Paramount Biosciences, LLC and The Lindsay A. Rosenwald 2000 Family Trusts Dated December 15, 2000; (iii) the series convertible promissory
notes issued by the Company on December 14, 2007; and (iv) the series convertible promissory notes issued by the Company on February 9, 2010 and March 1, 2010,
which Existing Convertible Notes have an aggregate original principal amount of $10,719,350; 

“FDA” shall mean the
United States Food and Drug Administration or any successor agency;

4

“FDA
Final Approval” shall mean approval by the FDA that is not conditioned on any other event (or if an approval is conditioned upon an event, then the
occurrence of that event), provided, however, such other events shall specifically not include FDA requirements to conduct post marketing studies and any
requirement for such post marketing studies shall not be deemed to delay the Final Approval;

“First Commercial Sale” shall mean the first
sale of the Product after all applicable marketing and pricing approvals (if any) have been granted by the applicable governing
health authority of such country;

“License Agreement”
shall mean the License Agreement dated as of June 12, 2007, between the Licensor and the Company, pursuant to which the Company licensed certain rights to the
Product, as the same may be amended from time to time;

“Licensor” shall mean
Dong Wha Pharm. Co. Ltd., a Korean corporation, or its successor;

“Milestone Payments”
shall mean the Development Milestone Payments and the Net Sales Payments;

“NDA” shall mean a New
Drug Application, or similar application for marketing approval of the Product submitted to the FDA;

“Net Sales” shall
mean, with respect to the Product, the gross sales price of the Product invoiced by the Company or its Affiliate to customers who are not Affiliates (or are
Affiliates but are the end users of the Product) less, to the extent actually paid or accrued by the Company or its Affiliate (as applicable), (a) credits,
allowances, discounts and rebates to, and chargebacks from the account of, such customers for nonconforming, damaged, out-dated and returned Product;
(b) freight and insurance costs incurred by the Company or its Affiliate (as applicable) in transporting the Product to such customers; (c) cash,
quantity and trade discounts, rebates and other price reductions for the Product given to such customers under price reduction programs; (d) sales, use,
value-added and other direct taxes incurred on the sale of the Product to such customers; (e) customs duties, tariffs, surcharges and other governmental
charges incurred in exporting or importing the Product to such customers; and (f) an allowance for uncollectible or bad debts determined in accordance with
generally accepted accounting principles;

“Net Sales Payment”
shall mean, for any calendar quarter, an amount equal to fifteen percent (15%) of Net Sales of the Product by the Company and its Affiliates during such
calendar quarter; provided that the Net Sales Payment for the calendar quarter during which the cumulative Net Sales by the Company and its Affiliates and
Sublicensees reach $150,000,000 shall be prorated to apply only to Net Sales during the period up to such time that such cumulative Net Sales amount is
achieved;

“Person” shall mean an
individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole
proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein;

5

“Phase III Clinical Trial” shall mean a human clinical trial in any country, the results of which could be used to establish safety and efficacy of
the Product as a basis for an NDA or would otherwise satisfy requirements of 21 C.F.R. 312.21(c);

“Pro Rata Share” shall
mean, with respect to any Milestone Payment, the Holder’s pro rata share of such Milestone Payment based on the original principal amount of this Note
relative to the aggregate original principal amount of all Existing Convertible Notes;

“Product” shall mean
the Company’s lead product candidate known as PB-101 (zabofloxacin);

“Rights Offering”
means a rights offering to the holders of the Existing Convertible Notes of a new issue of secured convertible notes in the aggregate principal amount of
$3,000,000;

“Sublicensee” means
any Third Party to whom the Company grants rights to use some of the Company’s rights under the License Agreement;

“Successful Completion” shall mean that the Phase III Clinical Trial (a) achieved its primary clinical endpoint as defined in the protocol for the Phase III Clinical
Trial and (b) had a side effect profile that does not adversely affect the Product’s eligibility to be subject to an NDA; and

“Third Party” shall
mean any Person other than the Company, the Licensor and their respective Affiliates.

“Trading Day” shall
mean a day on which the shares of Common Stock are traded on a national securities exchange, or, if the Common Stock are not so traded, a business day.

2.

Consent.  The Holder hereby consents
to the amendment to the Note as set forth in Section 1 hereof.

3.

Representations and Warranties of the Holder.
 The Holder hereby represents and warrants to the Company that: 

(a)

the Holder is the lawful holder of the Note free and clear of all
security interests, claims, liens, pledges, conditional sales contracts, attachments, judgments and encumbrances of every kind and nature, including
restrictions, or rights of any third parties;

(b)

the Holder has the requisite power and authority to execute and
deliver this Agreement, to perform the Holder’s obligations hereunder and to engage in the transactions contemplated hereby;

(c)

the Holder has taken all requisite action to make all the
provisions of this Agreement the valid and enforceable obligations they purport to be; and

(d)

this Agreement constitutes the valid and binding obligation of the
Holder, enforceable in accordance with its terms, subject to laws of general application from time to time

6

in effect affecting creditors' rights and the exercise of
judicial discretion in accordance with general equitable principles.

4.

Representations and Warranties of the Company.
 The Company hereby represents and warrants to the Holder that: 

(a)

it has the requisite power and authority to execute and deliver
this Agreement, to perform its obligations hereunder and to engage in the transactions contemplated hereby;

(b)

it has taken all requisite action to make all the provisions of
this Agreement the valid and enforceable obligations they purport to be; 

(c)

this Agreement constitutes its valid and binding obligation,
enforceable in accordance with its terms, subject to laws of general application from time to time in effect affecting creditors' rights and the exercise of
judicial discretion in accordance with general equitable principles; and

(d)

neither the execution, delivery or performance of this Agreement
nor the consummation of the transactions contemplated hereby violates, conflicts with, constitutes a default under, results in the acceleration of or creates in
any party the right to accelerate, terminate, modify or cancel any material contract to which it is a party or by which it is bound.

5.

Miscellaneous

(a)

This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party, it being understood that the parties need not sign the same counterpart.  In the event that any signature is
delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile signature page were an original thereof. 

(b)

This Agreement shall be governed by the law of the State
of New York without giving effect to any principles or conflicts of law. 

(c)

Except as expressly amended hereby, the terms of the Note
shall remain in full force and effect.

(d)

Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other
party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

(e)

Existing references to the Note are henceforth deemed
references to the Note as amended by this Agreement.

(f)

If any provision or portion of this Agreement shall be
determined to be invalid or unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall
remain in full force and effect to the fullest extent permitted by law.

7

(g)

The headings contained in this Agreement are for
reference purposes only and shall not be deemed to be part of this Agreement or to affect the meaning or interpretation of this Agreement.

(h)

All of the terms and provisions of this Agreement shall
bind and inure to the benefit of the parties hereto and their respective successors and assigns.

(i)

This Agreement is intended for the benefit of the parties
hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person or
entity.

  

[Remainder of page intentionally left blank]

8

IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 

				
	 
	IASO PHARMA
INC.

	  

	  

	  

	  

	  

	By: 

	/s/ Matthew A.
Wikler

	  

	Name: 

	 Matthew A. Wikler, M.D.

	  

	Title: 

	 President and CEO

	 
	 
	 
	 

 

				
	 
	CAPRETTI
GRANDI, LLC

	  

	  

	  

	  

	  

	By: 

	/s/ Lindsay A.
Rosenwald

	  

	Name: 

	Lindsay A. Rosenwald, M.D.

	  

	Title: 

	Managing Member

	 
	 
	 
	 

Capretti Note Amendment Agreement Signature PageExhibit 4.37

Warrant No. B-01

IASO PHARMA INC.

COMMON STOCK WARRANT

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THIS WARRANT IS SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO
REGISTRATION OR EXEMPTION THEREFROM. THE ISSUER OF THIS WARRANT MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE
ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT. 

This certifies that Manchester Securities Corp. (the
“Holder”), its designees or permitted assigns, subject to the terms and conditions set forth herein, at any time after the Qualified IPO (as
hereinafter defined) and prior to the Expiration Date (as defined below), is entitled to purchase from IASO Pharma Inc., a Delaware corporation (the “Company”), that number of fully-paid and non-assessable shares (subject to adjustment as provided herein) (the “Warrant Shares”) of
the Company’s Common Stock, $0.001 par value per share (the “Common Stock”), equal to the Holder Warrant Share Number (as defined below),
upon surrender to the Company at its principal office (or at such other location as the Company may advise the Holder in writing) of this Warrant properly
endorsed with the Form of Subscription attached hereto duly completed and signed and upon payment of the aggregate Exercise Price (as defined below) for the
number of Warrant Shares for which this Warrant is being exercised determined in accordance with the provisions hereof. For purposes hereof, “Qualified IPO” means the consummation of an underwritten initial public offering by the Company of shares of Common Stock resulting in aggregate net
cash proceeds (after commissions and other expenses) to the Company of at least $10,000,000. “Holder Warrant Share Number” means the
greater of (x) (i) $1,500,000, divided by (ii) the price at which shares of Common Stock are sold in a Qualified IPO and (y) the number of shares of Common
Stock equal to 9.99% of the aggregate number of shares of Common Stock outstanding upon consummation of the Qualified IPO on a fully diluted basis. The
exercise price (the “Exercise Price”) per Warrant Share issuable pursuant to this Common Stock Warrant shall be equal to the (I) Holder
Warrant Share Number, divided by (II) $1,500,000. For the avoidance of doubt, in no event will the aggregate Exercise Price of this Warrant exceed
$1,500,000.

This Warrant is issued subject to the following terms
and conditions:

1.

Exercise, Issuance of Certificates.
 Subject to Section 3(g) and Section 14 hereof, the Holder may exercise this Warrant, at any time or from time to time, during the period (a) commencing on
the Qualified IPO and (b) expiring at 5:00 p.m. (Eastern Time) on April 29, 2016 (the “Expiration Date”). The Holder may exercise this
Warrant on or prior to the Expiration Date for all or any part of the Warrant Shares (but not for a fraction of a share) that may be purchased hereunder, as
that number may be adjusted pursuant to Section of this Warrant. The Company

agrees that the Warrant Shares purchased
under this Warrant shall be and are deemed to be issued to the Holder hereof as the record owner of such Warrant Shares as of the close of business on the date
on which this Warrant shall have been surrendered, properly endorsed, the completed and executed Form of Subscription delivered, and payment made for such
Warrant Shares (such date, a “Date of Exercise”). Certificates for the Warrant Shares so purchased, together with any other securities or
property to which the Holder hereof is entitled upon such exercise, shall be delivered to the Holder hereof by the Company at the Company’s expense as soon
as practicable after the rights represented by this Warrant have been so exercised, but in any event not later than three (3) business days following the Date
of Exercise (the “Share Delivery Date”). Notwithstanding the foregoing, to the extent that (i) the Company’s transfer agent is
participating in The Depository Trust Company ("DTC") Fast Automated Securities Transfer Program and (ii) Warrants Shares so purchased do
not require the placement of any legends restricting transfer of such Warrant Shares pursuant to Section 6 hereof, upon the request of the Holder, the Company
Shall credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder's or its designee's balance account
with DTC through its Deposit Withdrawal Agent Commission system by the Share Delivery Date. In case of a purchase of less than all the Warrant Shares
which may be purchased under this Warrant, the Company shall cancel this Warrant and execute and deliver to the Holder hereof within a reasonable time a new
Warrant or Warrants of like tenor for the balance of the Warrant Shares purchasable under the Warrant surrendered upon such purchase;
provided, however, in no event shall the Holder be required to return this Warrant to the Company in connection with any exercise hereof. Each stock
certificate so delivered shall be registered in the name of such Holder and issued with a legend in substantially the form of the legend placed on the front of
this Warrant (except as set forth in Section 6 hereof). 

(a)

The Company’s obligations to issue and deliver
Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same.
 Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing
shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof (a “Share Delivery Failure”). The
Company will reimburse the Holder for any and all losses, damages and/or out-of-pocket expenses incurred by the Holder in connection with any Share Delivery
Failure. 

(b)

Payment of Exercise Price. The Holder shall
pay the Exercise Price by delivering immediately available funds to the Company.

2.

Shares to be Fully Paid; Reservation of Shares.
 The Company covenants and agrees that all Warrant Shares, will, upon issuance and payment of the applicable Exercise Price, be duly authorized, validly
issued, fully paid and nonassessable, and free of all preemptive rights, liens and encumbrances, except for restrictions on transfer provided for herein.
 The Company shall at all times reserve and keep available out of its authorized and unissued Common Stock, solely for the purpose of providing for the
exercise of the rights to purchase all Warrant Shares granted pursuant to this Warrant, such number of shares of Common Stock as shall, from time to time, be
sufficient therefor (“Required Reserve Amount”).  If at any time while this Warrant remains outstanding the Company does not have a
sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of this Warrant at least
the Required Reserve Amount (an "Authorized Share Failure"), then the Company shall as soon as practicable take all action necessary to
increase the Company's authorized shares of Common Stock to an amount

2

sufficient to allow the Company to reserve the
Required Reserve Amount for this Warrant then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the
date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90) days after the occurrence of such Authorized Share Failure, the
Company shall either (x) obtain the vote or written consent of its shareholders for the approval of an increase in the number of authorized shares of Common
Stock and provide each shareholder with an information statement with respect thereto or (y) hold a meeting of its shareholders for the approval of an increase
in the number of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each shareholder with a proxy statement and
shall use its reasonable best efforts to solicit its shareholders' approval of such increase in authorized shares of Common Stock and to cause its Board of
Directors to recommend to the shareholders that they approve such proposal.

3.

Adjustment of Exercise Price and Number of Shares
. The Exercise Price and the total number of Warrant Shares shall be subject to adjustment from time to time upon the occurrence of certain events
described in this Section 3.

(a)

Subdivision or Combination of Stock. In
the event the outstanding shares of the Company’s Common Stock shall be increased by a stock dividend payable in Common Stock, stock split, subdivision, or
other similar transaction occurring after the date hereof into a greater number of shares of Common Stock, the Exercise Price in effect immediately prior to
such subdivision shall be proportionately reduced and the number of Warrant Shares issuable hereunder proportionately increased. Conversely, in the event
the outstanding shares of the Company’s Common Stock shall be decreased by reverse stock split, combination, consolidation, or other similar transaction
occurring after the date hereof into a lesser number of shares of Common Stock, the Exercise Price in effect immediately prior to such combination shall be
proportionately increased and the number of Warrant Shares issuable hereunder proportionately decreased.

(b)

Reclassification. If any
reclassification of the capital stock of the Company or any reorganization, consolidation, merger, or any sale, lease, license, exchange or other transfer (in
one transaction or a series of related transactions) of all or substantially all, of the business and/or assets of the Company (the “Reclassification
Events”) shall be effected in such a way that holders of Common Stock shall be entitled to receive stock, securities, or other assets or property,
then, as a condition of such Reclassification Event, lawful and adequate provisions shall be made whereby the Holder hereof shall thereafter have the right to
purchase and receive (in lieu of the shares of Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights
represented hereby) such shares of stock, securities, or other assets or property as may be issued or payable with respect to or in exchange for a number of
outstanding shares of such Common Stock equal to the number of shares of such stock immediately theretofore purchasable and receivable upon the exercise of the
rights represented hereby. In any Reclassification Event, appropriate provision shall be made with respect to the rights and interests of the Holder of
this Warrant to the end that the provisions hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the number of Warrant
Shares), shall thereafter be applicable, as nearly as may be, in relation to any shares of stock, securities, or assets thereafter deliverable upon the exercise
hereof.

(c) Distributions of Assets.  If the Company shall declare or
make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off,
reclassification, corporate

3

rearrangement, scheme of arrangement or other similar transaction other
than a dividend or distribution payable solely in shares of Common Stock for which an adjustment is made pursuant to Section 3(a)) (a "Distribution
"), at any time after the issuance of this Warrant, then, in each such case:

(i)

any Exercise Price in effect immediately prior to the close of
business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as
of the close of business on such record date, to a price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall be the
Closing Bid Price (as defined below) of the shares of Common Stock on the trading day immediately preceding such record date minus the value of the Distribution
(as determined in good faith by the Company's Board of Directors) applicable to one share of Common Stock, and (ii) the denominator shall be the Closing Bid
Price of the Common Shares on the trading day immediately preceding such record date; and

(ii)

the number of Warrant Shares shall be increased to a number of
shares equal to the number of shares of Common Stock obtainable immediately prior to the close of business on the record date fixed for the determination of
holders of shares of Common Stock entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding
paragraph (i).

(iii) "Closing Bid Price" means, for any
security as of any date, the last closing bid price for such security on the principal securities exchange or trading market where
such security is listed or traded (the “Principal Market”), as
reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price, then the last bid
price of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg. If the Closing Bid Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Bid Price of such security on such date shall be the fair market value as mutually determined by the
Company and the Holder. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar
transaction during the applicable calculation period.

(d) 

Subsequent Equity Raises. During the period commencing on the date
of the Qualified IPO until after the Company has completed an aggregate of $25,000,000 in equity financings (excluding the initial IPO) (collectively, the
“Subsequent Equity Raises”), the number of Warrant Shares and the Exercise Price shall be permanently adjusted upon each issuance of Common
Stock or securities convertible into or exercisable for or exchangeable into Common Stock (collectively, “Equity Securities”) (or derivatives
thereon, whether settled in cash or Equity Securities) (excluding the Qualified IPO) such that upon exercise in full of this Warrant for an aggregate exercise
price of $1,500,000, the Holder would receive a number of Warrant Shares representing a percentage of the Common Stock outstanding immediately after the
issuance giving rise to the adjustment equal to the Holder Warrant Percentage (as defined below). No further adjustments pursuant to the preceding
sentence will be made following the completion of the Subsequent Equity Raises. In the event that the Company has not completed an aggregate of
$25,000,000 of Subsequent Equity Raises by March 30, 2016 (the “Automatic Adjustment Date”), then on such Automatic Adjustment Date the
number of Warrant Shares issuable upon exercise of this Warrant and the Exercise Price hereof shall be adjusted in accordance with this Section 3(d) as if on
the Automatic Adjustment Date the Company sold a number of shares of Common Stock equal to quotient of (1) the difference between (x) $25,000,000 and (y) the
proceeds of any Subsequent Equity Raises consummated prior to the Automatic Adjustment Date and (2) the closing price per

4

share of Common Stock on the Principal Market on the Automatic Adjustment
Date.  “Holder Warrant Percentage” means the percentage that the Holder Warrant Share Number represents of the aggregate number of
shares of Common Stock outstanding upon consummation of the Qualified IPO on a fully diluted basis.

(e) 

Other Events. If any event occurs of the type contemplated by the
provisions of this Section 3 but not expressly provided for by such provisions, then the Company's Board of Directors will make an appropriate adjustment in the
Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment pursuant to this Section 3(e) will
increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 3.   

(f)

Notice of Adjustment. Upon any adjustment of the Exercise Price or
any increase or decrease in the number of Warrant Shares, the Company shall give written notice thereof, by first class mail postage prepaid, addressed to the
registered Holder of this Warrant at the address of such Holder as shown on the books of the Company. The notice shall be prepared and signed by the
Company’s Chief Financial Officer and shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of
shares purchasable at such price upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such
calculation is based.

(g)

Sale of the Company. Notwithstanding any other provision of this
Section 3, following the Qualified IPO, upon the consummation by the Company (in one or a series of related transactions) of a merger, consolidation, sale or
transfer of more than fifty percent (50%) of the Company’s capital stock or all or substantially all of the Company’s assets determined on a
consolidated basis (a “Fundamental Transaction”), this Warrant shall terminate ninety (90) days following such consummation; provided that the
Holder has the right to exercise this Warrant pursuant to its terms during such 90-day period. In addition, in the event of a Fundamental Transaction, at the
request of the Holder delivered before the ninetieth (90th) day after the consummation of such Fundamental Transaction, the Company (or the Company’s
successor) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) business days after such request (or, if later, on the effective
date of the Fundamental Transaction), cash in an amount equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant
on the date of such Fundamental Transaction. "Black Scholes Value" means the value of this Warrant based on the Black and Scholes Option
Pricing Model obtained from the "OV" function on Bloomberg Financial Markets determined as of the day of the closing of the applicable Fundamental
Transaction for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term
of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg as of the day immediately following the public announcement of the applicable Fundamental Transaction, (iii) the underlying price per
share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non cash consideration, if any,
being offered in the Fundamental Transaction and (iv) a 365 day annualization factor.

4.

No Voting or Dividend Rights. Nothing
contained in this Warrant shall be construed as conferring upon the holder hereof the right to vote or to consent to receive notice as a stockholder of the
Company on any other matters or any rights whatsoever as a shareholder of the Company. No dividends or interest shall be payable or accrued in respect of
this Warrant or the interest represented

5

hereby or the shares purchasable
hereunder until, and only to the extent that, this Warrant shall have been exercised.

5.

Compliance with the Act. The Holder of this
Warrant, by acceptance hereof, agrees that this Warrant is being acquired for its own account and not for any other person or persons, for investment purposes
and that it will not offer, sell, or otherwise dispose of this Warrant except under circumstances which will not result in a violation of the Act or any
applicable state securities laws. 

6.

Limited Transferability. The Holder
represents that by accepting this Warrant it understands that this Warrant and any securities obtainable upon exercise of this Warrant have not been registered
for sale under Federal or state securities laws and are being offered and sold to the Holder pursuant to one or more exemptions from the registration
requirements of such securities laws. In the absence of an effective registration of such securities or an exemption therefrom, any certificates for such
securities shall bear the legend set forth on the first page hereof. The Holder understands that it must bear the economic risk of its investment in this
Warrant and any securities obtainable upon exercise of this Warrant for an indefinite period of time, as this Warrant and such securities have not been
registered under Federal or state securities laws and therefore cannot be sold unless subsequently registered under such laws, unless an exemption from such
registration is available.  Notwithstanding the foregoing or anything contained herein to the contrary, if the resale of the Warrant Shares by the
Holder is covered by an effective registration, then upon exercise of this Warrant the Company shall deliver such Warrant Shares to the Holder free of any
restrictive legends. 

7.

Amendment, Waiver, etc. Except as
expressly provided herein, neither this Warrant nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed
by the party against whom enforcement of any such amendment, waiver, discharge or termination is sought.

8.

Notices. Any notice, request, or other
document required or permitted to be given or delivered to the Holder hereof or the Company shall be delivered as set forth in the that certain Backstop
Commitment Agreement dated April 6, 2011 among the Company, Manchester Securities Corp. and Lindsay A. Rosenwald, M.D. (the “Backstop Agreement”).

9.

Governing Law; Jurisdiction. This Warrant
shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of New York without regard to the
conflicts of laws provisions thereof. The parties consent to the exclusive jurisdiction of the state and federal courts located in New York County, New
York for any action, suit or proceeding arising hereunder.

10.

Lost or Stolen Warrant. Upon receipt of
evidence reasonably satisfactory to the Company of the loss, theft, destruction, or mutilation of this Warrant and, in the case of any such loss, theft or
destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation, upon surrender and cancellation of such
Warrant, the Company, at its expense, will make and deliver a new Warrant, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant.

11.

Fractional Shares. No fractional shares
shall be issued upon exercise of this Warrant. The Company shall, in lieu of issuing any fractional share, pay the Holder entitled to such fraction a sum
in cash equal to such fraction (calculated to the nearest 1/100th of a share) multiplied by the then effective Exercise Price on the date the Form of
Subscription is received by the Company.

6

12.

Successors and Assigns. This Warrant and
the rights evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and assigns of the Holder.
 The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such
Holder.

13.

Severability of Provisions. In case any one or
more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions
of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision
which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

14.

Ownership Limitation. The
Company shall not effect any exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant, to the extent that after giving effect
to such exercise, such Holder (together with the Holder's affiliates) would beneficially own in excess of 9.99% (the "Maximum Percentage") of
the number of shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of this paragraph, beneficial ownership
shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "1934 Act"). For purposes of this
Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected
in (1) the Company's most recent Form 10-K, or Form 10-Q or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more
recent public announcement by the Company or (3) any other notice by the Company or the Company’s transfer agent setting forth the number of shares of
Common Stock outstanding. For any reason at any time, upon the written or oral request of the Holder, the Company shall within two (2) Business Days
confirm in writing to the Holder the number of shares of Common Stock then outstanding. By written notice to the Company, the Holder may from time to time
decrease the Maximum Percentage to any other percentage specified in such notice; provided that any such increase will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner other than in
strict conformity with the terms of this Section 14 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the
intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.

15.

Participation Rights. Upon any and all financings by the
Company of Equity Securities (a “Subsequent Financing”), the Holder shall have the right to participate in any such Subsequent Financing in
amount of up to $1,500,000. At least 20 days prior to the closing of the Subsequent Financing, the Company shall deliver to the Holder a written notice of
its intention to effect a Subsequent Financing (“Pre-Notice”), which Pre-Notice shall ask the Holder if it wants to review the details of such
financing (such additional notice, a “Subsequent Financing Notice”). Upon the Holder’s request made within 10 days after receipt of the
Pre-Notice, and only upon a request by the Holder, for a Subsequent Financing Notice, the Company shall promptly, but no later than 1 day after receipt of such
request, deliver a Subsequent Financing Notice to the Holder. The Subsequent Financing Notice shall describe in reasonable detail the proposed terms of
such Subsequent Financing, the amount of proceeds intended to be raised thereunder, the person with whom such Subsequent Financing is proposed to be effected,
and attached to which shall be a term sheet or similar document relating thereto. Notwithstanding the foregoing, the Holder may at any time, or from time
to time, deliver a written notice to the Company that it does not wish to receive any Pre-Notices or Subsequent Financing Notices and following receipt of such
notice the Company shall not deliver any Pre-Notices or Subsequent Financing Notices to the Holder until such notice is rescinded in writing by the Holder.
 This Section 15 shall survive any expiration, termination or exercise of this Warrant.

Remainder of Page Intentionally Left Blank; Signature
Page Follows

7

IN WITNESS WHEREOF, the Company has
caused this Warrant to be duly executed by its officer, thereunto duly authorized as of this 29th day of April, 2011.

				

	 
	IASO PHARMA INC.

	 
	 

	 
	 

	 
	By:

	
/s/ Matthew A. Wikler

	 
	 
	
Name:

	Matthew A. Wikler

	 
	 
	
Title:

	President and Chief Executive Officer

Signature Page—Common Stock Warrant

FORM OF SUBSCRIPTION

(To be signed only upon exercise of Warrant)

To:

IASO Pharma Inc.

The undersigned, the holder of the
attached Common Stock Warrant, hereby elects to exercise the purchase right represented by such Warrant for, and to purchase thereunder,
                                    shares of Common Stock of IASO Pharma Inc. and such holder herewith makes payment of $_________ therefor.

The undersigned requests that certificates
for such shares be issued in the name of, and 

delivered to:                                                                                                                                                                       

whose address is:                                                                                                                                                              .

 

DATED:                                 

                                                                                                         
(Signature must conform in all respects to name of Holder as

specified on the face of the Warrant)

Name:

                                                                                                          

Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]